Spain · Delayed Price · Currency is EUR Pharma Mar Statistics
Total Valuation
Pharma Mar has a market cap or net worth of EUR 1.67 billion. The enterprise value is 1.55 billion.
| Market Cap | 1.67B |
| Enterprise Value | 1.55B |
Important Dates
The last earnings date was Wednesday, April 29, 2026.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Jun 25, 2025 |
Share Statistics
Pharma Mar has 17.36 million shares outstanding.
| Current Share Class | 17.36M |
| Shares Outstanding | 17.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 12.04% |
| Owned by Institutions (%) | 10.38% |
| Float | 13.43M |
Valuation Ratios
The trailing PE ratio is 20.78 and the forward PE ratio is 22.47. Pharma Mar's PEG ratio is 0.29.
| PE Ratio | 20.78 |
| Forward PE | 22.47 |
| PS Ratio | 7.42 |
| PB Ratio | 6.70 |
| P/TBV Ratio | 6.80 |
| P/FCF Ratio | 27.55 |
| P/OCF Ratio | 24.59 |
| PEG Ratio | 0.29 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 21.49, with an EV/FCF ratio of 25.56.
| EV / Earnings | 19.28 |
| EV / Sales | 6.88 |
| EV / EBITDA | 21.49 |
| EV / EBIT | 24.08 |
| EV / FCF | 25.56 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.19.
| Current Ratio | 3.06 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 0.66 |
| Debt / FCF | 0.78 |
| Interest Coverage | 39.28 |
Financial Efficiency
Return on equity (ROE) is 35.99% and return on invested capital (ROIC) is 48.92%.
| Return on Equity (ROE) | 35.99% |
| Return on Assets (ROA) | 11.20% |
| Return on Invested Capital (ROIC) | 48.92% |
| Return on Capital Employed (ROCE) | 21.76% |
| Weighted Average Cost of Capital (WACC) | 6.18% |
| Revenue Per Employee | 446,398 |
| Profits Per Employee | 159,343 |
| Employee Count | 505 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.24 |
Taxes
| Income Tax | -15.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +21.02% in the last 52 weeks. The beta is 0.37, so Pharma Mar's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +21.02% |
| 50-Day Moving Average | 91.62 |
| 200-Day Moving Average | 82.74 |
| Relative Strength Index (RSI) | 47.56 |
| Average Volume (20 Days) | 70,093 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharma Mar had revenue of EUR 225.43 million and earned 80.47 million in profits. Earnings per share was 4.64.
| Revenue | 225.43M |
| Gross Profit | 212.91M |
| Operating Income | 64.42M |
| Pretax Income | 65.15M |
| Net Income | 80.47M |
| EBITDA | 70.27M |
| EBIT | 64.42M |
| Earnings Per Share (EPS) | 4.64 |
Balance Sheet
The company has 167.85 million in cash and 47.54 million in debt, with a net cash position of 120.32 million or 6.93 per share.
| Cash & Cash Equivalents | 167.85M |
| Total Debt | 47.54M |
| Net Cash | 120.32M |
| Net Cash Per Share | 6.93 |
| Equity (Book Value) | 249.67M |
| Book Value Per Share | 14.38 |
| Working Capital | 184.23M |
Cash Flow
In the last 12 months, operating cash flow was 68.00 million and capital expenditures -7.31 million, giving a free cash flow of 60.69 million.
| Operating Cash Flow | 68.00M |
| Capital Expenditures | -7.31M |
| Depreciation & Amortization | 5.85M |
| Net Borrowing | -7.26M |
| Free Cash Flow | 60.69M |
| FCF Per Share | 3.50 |
Margins
Gross margin is 94.45%, with operating and profit margins of 28.58% and 35.70%.
| Gross Margin | 94.45% |
| Operating Margin | 28.58% |
| Pretax Margin | 28.90% |
| Profit Margin | 35.70% |
| EBITDA Margin | 31.17% |
| EBIT Margin | 28.58% |
| FCF Margin | 26.92% |
Dividends & Yields
This stock pays an annual dividend of 0.80, which amounts to a dividend yield of 0.83%.
| Dividend Per Share | 0.80 |
| Dividend Yield | 0.83% |
| Dividend Growth (YoY) | 23.08% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 17.33% |
| Buyback Yield | n/a |
| Shareholder Yield | 0.83% |
| Earnings Yield | 4.81% |
| FCF Yield | 3.63% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 22, 2020. It was a reverse split with a ratio of 0.0833333333.
| Last Split Date | Jul 22, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.0833333333 |
Scores
Pharma Mar has an Altman Z-Score of 8.74 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.74 |
| Piotroski F-Score | 7 |